SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-002707
Filing Date
2022-02-15
Accepted
2022-02-15 16:13:56
Documents
13
Period of Report
2022-02-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cort-20220215.htm   iXBRL 8-K 32328
2 EX-99.1 exhibit991pressrelease02-1.htm EX-99.1 122709
  Complete submission text file 0001628280-22-002707.txt   303539

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cort-20220215.xsd EX-101.SCH 1943
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cort-20220215_lab.xml EX-101.LAB 24229
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cort-20220215_pre.xml EX-101.PRE 12634
7 EXTRACTED XBRL INSTANCE DOCUMENT cort-20220215_htm.xml XML 10575
Mailing Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025
Business Address 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 650.688.8803
CORCEPT THERAPEUTICS INC (Filer) CIK: 0001088856 (see all company filings)

IRS No.: 770487658 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50679 | Film No.: 22639317
SIC: 2834 Pharmaceutical Preparations